NEWS
NeW WAReHOuse sOLuTION FOR CAMBRIAN ALLIANCe
Cambrian Alliance Group, the uK’s largest independent pharmacy buying group, has announced the launch of a new platform designed to reduce dead stock and unnecessary spend within community pharmacy. The new platform, which is designed to work alongside the group’s existing purchasing tool, e-CAss, can also be deployed as a standalone platform for larger pharmacy groups with a more complex inventory management requirement. The launch represents another major development for the group following the unveiling of e-CAss web last year.
‘Our team have done a terrific job of developing another pharmacy-led platform that will really improve both operational and financial efficiency for our customers,’ said Nathan Wiltshire, CeO, Cambrian Group.
The group represents the buying needs of over 1200 independent pharmacy contractors across the uK and following a record year for new e-CAss customers in 2019, now has more than 850 users on the platform.
eTHOs trial yields positive results for COPD patients
Full results from the recent positive Phase III eTHOs trial showed AstraZeneca’s triple-combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
The randomised, double-blind, multi- centre, parallel-group study assessed the efficacy and safety of PT010 relative to PT003 (glycopyrronium/ formoterol fumarate) and PT009 (budesonide/formoterol fumarate) on COPD exacerbations over 52 weeks in people with moderate to very severe COPD. The dual-combination therapies used as comparators in the trial represent recommended
therapeutic classes for the treatment of COPD in appropriate patients.
The trial met its primary endpoint demonstrating that PT010 reduced the rate of moderate or severe COPD exacerbations by 24 per cent compared with PT003 (rate ratio, 0.76; 95 per cent confidence interval [CI], 0.69–0.83; P<0.001 at dose
320/14.4/9.6 µg; model-estimated annual rate of moderate or severe COPD exacerbations 1.08 vs 1.42). PT010 achieved a 13 per cent reduction in moderate or severe COPD exacerbations compared with PT009 (rate ratio, 0.87; 95 per cent CI, 0.79–0.95; P=0.003 dose
320/14.4/9.6 µg; model-estimated annual rate of moderate or severe COPD exacerbations 1.08 vs 1.24).
In a secondary endpoint*, PT010 showed a 46 per cent reduction in the risk of all-cause mortality
compared with PT003 (hazard ratio, 0.54; 95 per cent CI, 0.34-0.87; at
dose 320/14.4/9.6 µg; patient deaths - 28 (1.3 per cent) vs 49 deaths (2.3 per cent).
‘COPD is a progressive disease where exacerbations can be fatal for many of the millions of people who suffer with this condition,’ said Professor Dave singh, university of Manchester, Medical Director, Medicines evaluation unit. ‘The results from the phase III eTHOs trial clearly demonstrate that PT010 can reduce the rate of exacerbations and could potentially transform treatment goals in COPD.”’
The results were published in the New england Journal of Medicine and were presented at the American Thoracic society virtual scientific symposium, Clinical Trial Results in Pulmonary Medicine.
CBD capsules encourage health and wellbeing
elixinol’s new range of blended CBD capsules combines full-spectrum hemp oil with plant-based, vegan- friendly ingredients, vitamins, and minerals to target selected inner systems while encouraging good health and wellbeing. The blended capsules are rich in CBD and, as such, boast a complete range of cannabinoids, flavonoids, and terpenes.
The seven formulations are colour- coded for simple selection with a single, descriptive keyword relating each unique blend to its suggested application:
• Immune booster - Vitamin C, Vitamin B6 and Zinc to support the immune system
• Dreams - Chamomile, Ashwagandha and Thiamine for normal psychological function
• Harmony - Baobab and Chromium to help maintain normal blood glucose levels
• Digest - Inulin and Live Bacteria (L. Acidophilus and B. Bifidum) as well as calcium to assist digestive enzymes
• Turmeric - combined with Black Pepper, Vitamin C and
Pastures new for Harpreet sawhney
Nathan Wiltshire, CEO, Cambrian Alliance Group
46 - PHARMACY IN FOCus
Harpreet sawhney has joined Gedeon Richter uK as Commercial Manager uK and Ireland. Harpreet joins the company after more than twelve years as Commercial Manager at Consilient Health and will now be responsible for identifying, creating, developing and servicing existing customer accounts for Gedeon
Richter’s women’s health portfolio in the uK and Ireland.
Harpreet is a highly-experienced sales Manager with a demonstrated history of working in the pharmaceuticals industry and a specific focus on women’s health. In his new role, he will be liaising with regional and
national full and short-line wholesalers, key retail pharmacy chains, pharmacy buying groups and independent and national superstore pharmacy chains.
Manganese for bones, cartilage and connective tissue
• Allure - Niacin and selenium for skin, hair and nails
• serene - Biotin & Pantothenic Acid for normal mental performance
For more information, please visit
www.elixinol.co.uk. You can also email
hhsales@elixinol.com or call 0208 190 0623.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
